NCT04096742 is a Phase 4 clinical trial of tretinoin 0.05% lotion (Altreno) in Photodamaged Skin, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.

Who is sponsoring NCT04096742?

NCT04096742 is sponsored by Goldman, Butterwick, Fitzpatrick and Groff.

What drugs are being tested in NCT04096742?

Interventions in NCT04096742: tretinoin 0.05% lotion (Altreno), Vehicle.

What condition does NCT04096742 study?

NCT04096742 studies Photodamaged Skin, Photoaging.

Is NCT04096742 still recruiting?

NCT04096742 is currently status unknown. Last updated 2 April 2021.

Last reviewed 2021-04-02 · How we verify

NCT04096742

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Altreno for Chest Rejuvenation

Status unknown Phase 4 Last updated 2 April 2021

What this trial tests

Phase 4 trial testing tretinoin 0.05% lotion (Altreno) in Photodamaged Skin in 40 participants. Status unknown.

Timeline

6 August 2019

Primary endpoint
30 July 2021

31 December 2021

Quick facts

Lead sponsor	Goldman, Butterwick, Fitzpatrick and Groff
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	40
Start date	6 August 2019
Primary completion	30 July 2021
Estimated completion	31 December 2021
Sites	1 location across United States

Drugs / interventions tested

tretinoin 0.05% lotion (Altreno) — full drug profile →
Vehicle

Conditions studied

Photodamaged Skin — all drugs for Photodamaged Skin →
Photoaging — all drugs for Photoaging →

Sponsor

Goldman, Butterwick, Fitzpatrick and Groff — full company profile →

Who can join

Adults 18 to 65, any sex, with Photodamaged Skin or Photoaging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, prospective, double-blind, randomized, vehicle-controlled study to evaluate the efficacy, safety and patient satisfaction of tretinoin 0.05% lotion (Altreno) for chest rejuvenation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Goldman, Butterwick, Fitzpatrick and Groff trials

Trials by the same sponsor.

NCT07462533 — Assess Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing · Phase 2 · not yet recruiting
NCT07421544 — Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines · Phase 4 · not yet recruiting
NCT07342413 — Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the · Phase 4 · not yet recruiting
NCT07221461 — Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists · Phase 2 · not yet recruiting
NCT07217743 — Assess Impact of Poly-L-lactic Acid on GLP1 Subjects · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04096742 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Goldman, Butterwick, Fitzpatrick and Groff
Last refreshed: 2 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04096742.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing